ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: ACCC Celebrates 25th: James Hospital Receives Large Donations

April 9, 1999

FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer

May 31, 2013

Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting

June 20, 1986

EARLY Breast Cancer Screening Bill Gains Traction Among Jewish Groups

June 19, 2009

House Democrats Take More Swings At Tobacco Industry

February 17, 1989

NCI clinical trials cooperative group chairmen reject specimen bank contract proposal, endorse cooperative agreements;

January 2, 2004